CA2575000A1 - Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih - Google Patents

Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih Download PDF

Info

Publication number
CA2575000A1
CA2575000A1 CA 2575000 CA2575000A CA2575000A1 CA 2575000 A1 CA2575000 A1 CA 2575000A1 CA 2575000 CA2575000 CA 2575000 CA 2575000 A CA2575000 A CA 2575000A CA 2575000 A1 CA2575000 A1 CA 2575000A1
Authority
CA
Canada
Prior art keywords
hiv
host
gene
immunoassay according
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2575000
Other languages
English (en)
Inventor
Steven Sui Hu
Catherine C.Q. Shi
Richard A. Galli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOLYTICAL LABORATORIES Inc
Original Assignee
BIOLYTICAL LABORATORIES INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOLYTICAL LABORATORIES INC. filed Critical BIOLYTICAL LABORATORIES INC.
Priority to CA 2575000 priority Critical patent/CA2575000A1/fr
Priority to PCT/CA2008/000238 priority patent/WO2008095298A1/fr
Priority to PCT/CA2008/000239 priority patent/WO2008095299A1/fr
Publication of CA2575000A1 publication Critical patent/CA2575000A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA 2575000 2007-02-09 2007-02-09 Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih Abandoned CA2575000A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA 2575000 CA2575000A1 (fr) 2007-02-09 2007-02-09 Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih
PCT/CA2008/000238 WO2008095298A1 (fr) 2007-02-09 2008-02-08 Gène enveloppe synthétique du vih-i permettant d'optimiser son expression dans une bactérie utilisée lors de dosages immunologiques d'anticorps du vih-i
PCT/CA2008/000239 WO2008095299A1 (fr) 2007-02-09 2008-02-08 Gène synthétique de l'enveloppe du vih-2 permettant d'optimiser son expression dans une bactérie utilisée lors de dosages immunologiques d'anticorps du vih-2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2575000 CA2575000A1 (fr) 2007-02-09 2007-02-09 Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih

Publications (1)

Publication Number Publication Date
CA2575000A1 true CA2575000A1 (fr) 2008-08-09

Family

ID=39678517

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2575000 Abandoned CA2575000A1 (fr) 2007-02-09 2007-02-09 Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih

Country Status (2)

Country Link
CA (1) CA2575000A1 (fr)
WO (2) WO2008095299A1 (fr)

Also Published As

Publication number Publication date
WO2008095298A1 (fr) 2008-08-14
WO2008095299A1 (fr) 2008-08-14

Similar Documents

Publication Publication Date Title
EP0370458B1 (fr) Antigènes à partir d'ADN synthétique dérivé du virus de l'immunodéficience humaine (HIV-1) recombinant
US4784941A (en) Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JP2886861B2 (ja) エイズ関連症の検出用合成抗原
JPS61173782A (ja) リンパ節疾患症候群および／または後天性免疫不全症候群に関連する組換えウイルスタンパク質
NZ230855A (en) Principal neutralising domain of hiv variant, dna, vaccine, assay, antibodies and treatment
KR960005181B1 (ko) 재조합 htlv-ⅲ 단백질 및 이의 용도
CN114773487A (zh) 一种流感病毒和新型冠状病毒融合重组蛋白疫苗免疫原及其制备方法
CA2139517A1 (fr) Conjugues immunologiques d'epitopes de neutralisation principaux, propres au vih
JP4166940B2 (ja) Ｈｉｖウイルスに対して免疫反応性である抗体の検出用の合成抗原
AU627738B2 (en) Htlv-i / hiv-1 fusion proteins
WO1991007664A1 (fr) Proteines de diagnostic utilisees pour tester plus d'un anticorps
CA2575000A1 (fr) Genes env de synthese vih-1 et vih-2 pour l'optimisation de l'expression des bacteries destines aux immuno-essais des anticorps anti-vih
JPH01193299A (ja) 組替ｈｔｌｖ−３蛋白質及びその用途
CA2431881C (fr) Polypeptide induisant des anticorps neutralisant le vih
GB2282379A (en) Conjugates of epitopes of HIV with a protein complex from Neisseria
Sohn et al. Overexpression and purification of human immunodeficiency virus type 1 env derived epitopes in Escherichia coli
Gupta et al. Expression, purification, and characterization of an anti-RBCFab-p24 fusion protein for hemagglutination-based rapid detection of antibodies to HIV in whole blood
WO1996027012A1 (fr) Antigenes specifiques du vih-1, groupe o
CN114853910B (zh) 一种具有免疫原性的绵羊肺炎支原体hsp70-p113融合蛋白
US6861253B2 (en) Polypeptide inducing antibodies neutralizing HIV
Sohn et al. Rapid and simple purification of human immunodeficiency virus 1 epitope gp41
US20050287524A1 (en) Differential serological diagnosis of equine infectious anemia virus infected and vaccinated horses using recombinant S2 protein
KR100400666B1 (ko) 효모를 이용한 삼일열 말라리아 원충 표면 단백질의제조방법
WO1991004038A1 (fr) Antigene et immunotitrage pour la recherche du virus de l'immunodeficience humaine de type 2
CN101440129A (zh) 抗hiv-1外膜嵌合蛋白的单克隆抗体

Legal Events

Date Code Title Description
FZDE Dead